<DOC>
	<DOCNO>NCT00940407</DOCNO>
	<brief_summary>The purpose study evaluate clinical outcome Photobiomodulation treatment patient dry Age Related Macular Degeneration ( AMD ) . Photobiomodulation use non thermal , non laser light specific wavelengths energy directly eye improve retinal function delay AMD progression . This prospective 2 center phase 2 clinical pilot study placebo group .</brief_summary>
	<brief_title>Toronto Oak Ridge Photobiomodulation Study Dry Age Related Macular Degeneration</brief_title>
	<detailed_description>Dry AMD progressive sight threaten disease affect central acute vision . Dry AMD may progress wet form leak bleed retina cause sudden severe visual loss . There proven active treatment Dry AMD . Dry AMD account 80 % AMD case . There estimate 30 million people afflict AMD year 2020 North America . Photobiomodulation study utilise use two device already approve indication FDA Health Canada . Photobiomodulation novel clinical application treat dry AMD . As pilot study placebo control group .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Geographic Atrophy</mesh_term>
	<criteria>patient gender age 50 year inclusive patient must DRY macular degeneration study eye best correct visual acuity 20/40 20/200 patient must competent sign sign consent form study entry visually significant cataract presence visually significant posterior capsule prior cataract perform visually significant disease process ocular structure would affect vision unrelated macular degeneration patient enrol one eye meet criteria patient severe clinically significant medical disease unstable medical condition include cardiovascular , hepatic , renal , neurological , endocrine , gastrointestinal , CNS life threaten disease current malignancy discretion investigator patient nonambulatory bed ridden female patient pregnant childbearing potential effect PBM develop fetus unknown patient history epilepsy patient history alcohol , drug substance abuse past 6 month patient deem uncooperative non compliant requirement protocol patient receive investigational drug treatment within 30 day prior study entry patient competent understand sign consent form</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>dry AMD</keyword>
	<keyword>light treatment</keyword>
	<keyword>ARMD</keyword>
	<keyword>photobiomodulation</keyword>
	<keyword>macular</keyword>
	<keyword>eye disease</keyword>
	<keyword>age eye disease</keyword>
</DOC>